Recent

% | $
Quotes you view appear here for quick access.

Zalicus AŞ Message Board

scistats 323 posts  |  Last Activity: 12 hours ago Member since: Apr 5, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • scistats scistats Jun 9, 2016 1:22 PM Flag

    Where is our Allergan collaboration income???
    Where is it???
    When???
    How long do we have to wait???

    Allergan
    In November 2013, we entered into an agreement with Actavis (now Allergan) where Merrimack will utilize its proprietary nanoliposomal technology platform to develop and manufacture various pharmaceutical products for Actavis to commercialize around the world. We will produce bulk drug product at our Cambridge, MA nanoliposomal manufacturing facility.

    Sentiment: Strong Buy

  • Will CEO Mulroy move MACK to IEX Trading?
    If not, why???

    Sentiment: Strong Buy

  • "Before clinical translation can be realized, however, serious
    limitations with the in vivo delivery of mRNA must still be
    overcome. The high anionic charge density, size, and hydrophi-
    licity of nucleic acids prevent meaningful levels of passive dif-
    fusion of mRNA across cell membranes. To circumvent this
    barrier, our group and others have developed and implemented
    an array of lipid nanoparticles (LNPs) for the entrapment and
    subsequent delivery of nucleic acids in vivo. Although these
    LNPs have been largely optimized for siRNA sequences, both
    Schlake and co-workers and our research team have recently
    employed LNPs derived from previously described components
    to deliver mRNA in vivo. Successful delivery was confi rmed by
    quantifying serum protein levels, thereby establishing LNPs as
    viable delivery vehicles for mRNA.

    Inspired by these results, we sought to design and synthesize
    novel LNP components capable of delivering mRNA with unprec-
    edented levels of in vivo effi cacy. In practice, LNPs are composed
    of cholesterol (aids in stability), a phospholipid (modifi es bilayer
    structure), a polyethylene glycol (PEG) derivative (decreases
    aggregation and nonspecifi c uptake), and an ionizable lipid
    (complexes negatively charged RNA and enhances endosomal
    escape). Evidence within the siRNA delivery community has
    implicated the chemical structure and identity of the ionizable
    lipid as the most pivotal component for effi cacy. Accordingly,
    several rationally designed and combinatorial chemistry methodologies have been explored to discover novel series of ion-izable lipid materials capable of maximizing gene silencing at the
    lowest possible dose. This strategy both conserves precious thera-
    peutic nucleic acid cargo and also serves to mitigate any possible
    issues with the toxicity of the LNPs themselves."

    Adv Mater. 2016 Apr;28(15):2939-43

    Sentiment: Strong Buy

  • Reply to

    MM-161 & MM-436 are RNAi loaded

    by scistats May 28, 2016 10:28 AM
    scistats scistats Jun 9, 2016 9:18 AM Flag

    Bump!

    Sentiment: Strong Buy

  • In September 2014, Baxter Healthcare chose 650 East Kendall Street to be its flagship location in Cambridge, for a new global innovation and research and development (R&D) center at the site for its biopharmaceuticals business, which became a separate, independent global company known as Baxalta Incorporated. 650 East Kendal will house Baxalta’s CANCER THERAPY and business development operations. Baxalta will occupy 206,000 square feet. The building is owned by BioMed Realty Trust, Inc.

    Sentiment: Strong Buy

  • With its $32 billion purchase of Baxalta Inc. taking effect Friday, Shire PLC said it plans to retain and expand Baxalta’s drug research outpost in Kendall Square.

    The takeover, one of the largest life sciences deals of 2016, leave Shires — based in Ireland for tax purposes but run out of Lexington — with more than 3,000 workers in Massachusetts, making it the state’s second largest biopharma employer, after Sanofi Genzyme.

    Shire chief executive Flemming Ornskov said in an interview that his company plans to expand Baxalta’s 400-person research center at 650 E. Kendall St. by 100 to 200 jobs. He said he would also keep an office at the research center as a window on the entrepreneurial activity in the area.

    “We’re increasing our activity in the Massachusetts area,” said Ornskov, a Danish doctor-turned-dealmaker who has become one of the industry’s most aggressive acquirers in recent years. “This is de facto one of the world’s premier hubs for biotech research. It’s great for Shire now to be in the flow of a place that’s one of the world’s centers for innovation.”

    Baxalta, formed last summer when health care conglomerate Baxter International spun off its biosciences business, is focusing on hemophilia, immunology, and cancer drug development in Cambridge. The company opened the research center in Kendall Square last December.

    Sentiment: Strong Buy

  • Reply to

    Shire spotlights Boston-area base, cancer R&D

    by scistats Jun 8, 2016 9:18 PM
    scistats scistats Jun 8, 2016 9:19 PM Flag

    by John Carroll | Jun 3, 2016 9:20am

    Sentiment: Strong Buy

  • There were times during Shire’s slow-motion takeover of Baxalta that journalists joked that they had forgotten that the M&A effort was still on. But on Friday the two companies reached the end of a long set of negotiations, formally completing a $32 billion merger that creates a big biopharma company with 22,000 staffers worldwide focused primarily on rare diseases.

    The next big step will be slicing out the $500 million in “synergies” that were promised with the deal--which presumably includes axing an uncertain number of jobs in the process. But Shire settled at least one mystery about its R&D structure on the first day. Shire CEO Flemming Ornskov told The Boston Globe that he plans to keep Baxalta’s new research outpost on Kendall Square, the heart of the regional biotech hub, even looking to add anywhere from 100 to 200 researchers in the process.

    “We’re increasing our activity in the Massachusetts area,” Ornskov told the friendly hometown newspaper. “This is de facto one of the world’s premier hubs for biotech research. It’s great for Shire now to be in the flow of a place that’s one of the world’s centers for innovation.”

    Shire may be based in Dublin for tax purposes, but under Ornskov the company has been concentrating heavily around the campus in Lexington, MA. Last year Shire ripped up much of its organization in Pennsylvania as Ornskov accelerated that process, moving hundreds of jobs to Massachusetts.

    Ornskov still has a long way to go to deliver on a promise to increase revenue to more than $20 billion a year. One aspect of that campaign was highlighted in the merger release today, as Shire heralded the growing cancer drug franchise it acquired in the deal.

    Sentiment: Strong Buy

  • MERRIMACK HEALTHCARE SOLUTIONS is hiring

    Merrimack Oncology Partner - Kansas City (Kansas, W. Missouri)
    Merrimack Oncology Partner - Little Rock (Arkansas, Oklahoma, Louisiana)
    Merrimack Oncology Partner - Miami, FL (Orlando, Boca Raton, Fort Lauderdale, Miami)
    Merrimack Oncology Partner – San Francisco, CA
    Merrimack Oncology Partner - Southeast (Baltimore/DC/Northern Virginia)
    Merrimack Oncology Partner - Upstate New York (Albany, Syracuse, Rochester)
    Product Availability and Access Coordinator

    Sentiment: Strong Buy

  • At these levels, I concur with Zacks.

    "Cambridge, MA-based Merrimack Pharmaceuticals, Inc. MACK has transitioned from a development-stage company to a commercial-stage company following the FDA approval of cancer treatment, Onivyde, in Oct 2015. Onivyde is off to an encouraging start and its addition to the National Comprehensive Cancer Network (NCCN) 2016 Clinical Practice Guidelines in Oncology as a category I Treatment Option should also boost sales. This Zacks Rank #2 (Buy) stock is working on expanding Onivyde’s label and has several interesting candidates in its pipeline for different types of cancer."

    Sentiment: Strong Buy

  • scistats scistats Jun 6, 2016 8:54 PM Flag

    Dave was sacked for not buying MACK when he had the chance.
    He will be missed.

    Sentiment: Strong Buy

  • MM-151 shows positive clinical activity in phase 1 study of multiple solid tumor types

    MM-151 is an oligoclonal therapeutic consisting of a mixture of 3 fully human monoclonal antibodies designed to bind and inhibit signaling of the epidermal growth factor receptor (EGFR). EGFR-mediated signaling promotes the growth and survival of cancer cells and has long been recognized as an important drug target in several types of cancer, including colon, lung, breast, pancreatic, and head and neck cancers. MM-151 is a mixture of 3 independent antibodies, binding to 3 nonoverlapping sites on EGFR to maximize inhibition of ligand-dependent and independent signaling.

    Sentiment: Strong Buy

  • scistats scistats Jun 6, 2016 10:11 AM Flag

    Ask and ye shall receive.

    Sentiment: Strong Buy

  • Reply to

    New HERMIONE publication.

    by scistats Jun 5, 2016 3:49 PM
    scistats scistats Jun 5, 2016 3:50 PM Flag

    Figure 2 is cool.

    Sentiment: Strong Buy

  • BMC Cancer. 2016 Jun 3;16(1):352.

    HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.

    Sentiment: Strong Buy

  • Reply to

    The Guardian Article

    by pylesm Jun 4, 2016 1:25 AM
    scistats scistats Jun 4, 2016 9:36 AM Flag

    Now, if we put those two in an antibody decorated liposome for increased targeting and concentration, I wonder how much better would it be?

    Sentiment: Strong Buy

  • Reply to

    The Guardian Article

    by pylesm Jun 4, 2016 1:25 AM
    scistats scistats Jun 4, 2016 9:16 AM Flag

    The study enrolled patients following pancreatic cancer surgery.

    "Although most people diagnosed with pancreatic cancer are not candidates for surgery, the findings show that those who can have surgery "have a fighting chance of surviving this cancer with the combination of two commonly used chemotherapies," said John Neoptolemos, the study's lead author of the University of Liverpool in Britain."

    Sentiment: Strong Buy

  • scistats scistats Jun 3, 2016 9:56 PM Flag

    Dollar cost average your Roth contributions.
    90 percent Vanguard S&P 500, 10 percent gold ETF.

    Sentiment: Strong Buy

  • Title Committee for Medicinal Products for Human Use (CHMP): 20-23 June 2016
    Date 20/06/2016 - 23/06/2016
    Location European Medicines Agency, London, UK
    Summary The Committee for Medicinal Products for Human Use (CHMP) is the committee that is responsible for preparing the Agency's opinions on all questions concerning human medicines.

    Sentiment: Strong Buy

  • Big Pharma battle for $20 billion annual cited by CEO Gil Van Bokkelen Ph.D. as largest indication ever.
    About to begin.
    What's happening over in Mesoblast land?

    Sentiment: Strong Buy

ZLCS
0.00(0.00%)